FTC says CVS, Cigna, and UnitedHealth abuse middleman role. The interior of a CVS pharmacy store is seen on Aug. 7, 2024 in Austin, Texas. Brandon Bell/Getty. Units of CVS ...

CVS Health, UnitedHealth Group and Cigna sued the Federal Trade Commission, claiming the agency's case against drug middlemen over high insulin prices in the U.S. is unconstitutional.

CVS Health, Cigna and UnitedHealth Group are demanding that FTC Chairwoman Lina Khan and two other commissioners recuse themselves from a lawsuit accusing the company and other drug middlemen of ...

The Federal Trade Commission on Friday filed an administrative complaint against the three largest pharmacy benefit managers and their affiliated group purchasing organizations, alleging they have ...

CVS, Cigna and UnitedHealth are suing the Federal Trade Commission in a bid to block the agency’s lawsuit against their pharmacy benefit managers for allegedly inflating U.S. insulin prices.

The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing the drug middlemen of engaging in illegal rebate programs that drove up ...

CVS, UnitedHealth and Cigna in October asked the FTC to disqualify Chair Linda Khan from the insulin suit, citing alleged bias against their pricing model.

The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes patients towards higher priced insulin.

One of the country’s biggest pharmacy-benefit managers, Cigna Group’sCI0.64%increase; green up pointing triangle Express Scripts, sued the Federal Trade Commission, demanding a retraction of a ...

The Federal Trade Commission is planning to sue UnitedHealth, Cigna and CVS Health -- the three largest pharmacy-benefit managers -- over their tactics for negotiating prices for drugs including ...

The FTC said CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx profit at the expense of patients forced to pay more for insulin.

The FTC claims CVS Health's Caremark, Cigna's ESI, United Health Group's OptumRx created a "perverse drug rebate system," resulting in higher insulin list prices.